NexGel, Inc Warrant

NEXGEL, Inc. has moved up its shareholder update conference call from April 23rd to April 21st, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. The call will be available via phone and webcast for investors seeking updates on the transaction.

NexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focuse...

NEXGEL has created a spin-off company, NexGelRx, to focus exclusively on developing prescription drug delivery solutions using its proprietary hydrogel technology. NEXGEL will retain a 19.99% non-dilutive equity stake and receive a 5% perpetual global royalty.

NEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.

NEXGEL, Inc. announced it will report its financial results for the first quarter of 2025 on May 13, 2025. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.